Two-part webinar will provide data on recent FDA inspections, an overview of emerging compliance issues and strategies for responding to an FDA 483 in order to avoid an FDA warning letter.

Two-part webinar will provide data on recent FDA inspections, an overview of emerging compliance issues and strategies for responding to an FDA 483 in order to avoid an FDA warning letter.

Dietary supplement contract manufacturers and their “own-label distributor” customers must navigate a host of issues in order to establish effective business partnerships that ensure quality and compliance with federal laws and regulations

Tips for handling every aspect of a Food and Drug Administration (FDA) inspection--from pre-inspection preparation to interacting with on-site inspectors--and how to respond to observations and warning letters

tips for handling every aspect of a FDA inspection, from pre-inspection preparation to interacting with on-site inspectors, and responding to observations and warning letters

Industry experts will provide attendees with an insider's view of where FDA focuses its efforts during dietary supplement cGMP inspections to help participants fulfilling their all-important compliance efforts.

This webinar focuses on a number of regulatory compliance challenges that the dietary supplement industry encounters in its efforts to navigate regulatory compliance while creating successful product marketing campaigns.

Variances--an exception or departure from approved protocol--occur and this webinar will help you prepare for them.

A panel of experts help attendees understand the key elements of FDA's New Dietary Ingedient (NDI) draft guidance and how it will impact businesses in the supplement industry.

As much as 30% of the national sales of dietary supplements may be to California consumers - but companies that market in that state may encounter high penalties for non-compliance with a California law known as Proposition 65. The focus of this law for the supplement class has been on the warnings required for products that may inadvertently contain small amounts of heavy metals, such as arsenic, cadmium, and mercury, and especially lead.

This Guidance for Addressing FDA Inspections of Dietary Supplement Facilities has been prepared to assist AHPA members in understanding their rights and obligations when the U.S. Food and Drug Administration conducts an inspection of a facility in which dietary supplements or ingredients are manufactured, processed, packed or held. It provides descriptions and analyses of the current federal laws that are relevant to inspection of dietary supplement facilities and suggestions of how to prepare for and conduct inspections in a manner that fully complies with these laws.

This webinar covers the extent of FDA's authority during an inspection, so you know your rights.